BAPTA-AM, an intracellular calcium chelator, inhibits RANKL-induced bone marrow macrophages differentiation through MEK/ERK, p38 MAPK and Akt, but not JNK pathways

Cytokine

Volumn 52, Issue 3, 2010, Pages 210-214

  Zhou, Sigui ^a   Yuan, Xi ^d   Liu, Qinghua ^c   Zhang, Xiaoqi ^b   Pan, Xuediao ^a   Zang, Linquan ^a   Xu, Lipeng ^b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c SHIHEZI UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bone marrow macrophage; Calcium; MAPKs; Osteoclastogenesis; Receptor activator of nuclear factor B ligand

Indexed keywords

1,2 BIS(2 AMINOPHENOXY)ETHANE N,N,N',N' TETRAACETIC ACID TETRA(ACETOXYMETHYL) ESTER; CALCIUM CHELATING AGENT; CALCIUM ION; COLONY STIMULATING FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 1,2 BIS(2 AMINOPHENOXY)ETHANE N,N,N',N' TETRAACETIC ACID ACETOXYMETHYL ESTER; 1,2-BIS(2-AMINOPHENOXY)ETHANE N,N,N',N'-TETRAACETIC ACID ACETOXYMETHYL ESTER; CALCIUM; CHELATING AGENT; DRUG DERIVATIVE; EGTAZIC ACID; PROTEIN KINASE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BONE MARROW; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METABOLISM; OSTEOBLAST; PHOSPHORYLATION; PHYSIOLOGY; SPECTROFLUOROMETRY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CALCIUM; CELL DIFFERENTIATION; CHELATING AGENTS; EGTAZIC ACID; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; OSTEOBLASTS; PHOSPHORYLATION; PROTEIN KINASES; RANK LIGAND; SPECTROMETRY, FLUORESCENCE;

EID: 79953083276     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.07.003     Document Type: Article

References (29)

1. Ueki Y., Lin C.Y., Senoo M., Ebihara T., Agata N., Onji M., et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 " cherubism" mice. Cell 2007, 128:71-83.
2. Lee S.H., Kim T., Jeong D., Kim N., Choi Y. The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation. J Biol Chem 2008, 283:11526-11534.
3. Wittrant Y., Gorin Y., Mohan S., Wagner B., Abboud-Werner S.L. Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts. Endocrinology 2009, 150:4977-4988.
4. Anandarajah A.P. Role of RANKL in bone diseases. Trends Endocrinol Metab 2009, 20:88-94.
5. Leibbrandt A., Penninger J.M. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 2008, 1143:123-150.
6. Zheng B., Fiumara P., Li Y.V., Georgakis G., Snell V., Younes M., et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003, 102:1019-1027.
7. Liu W., Wang S., Wei S., Sun L., Feng X. Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. J Biol Chem 2005, 280:43064-43072.
8. Karsdal M.A., Hjorth P., Henriksen K., Kirkegaard T., Nielsen K.L., Lou H., et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 2003, 278:44975-44987.
9. 2+. Arch Surg 2000, 135:1432-1442.
10. 2+ as a propagator of CNS communication-integration of mitochondrial transport mechanisms and cellular responses. J Bioenerg Biomembr 2000, 32:5-13.
11. 2+ release in smooth muscle. Proc Natl Acad Sci USA 2009, 106:11418-11423.
12. Peng J., Bencsik M., Louie A., Lu W., Millard S., Nguyen P., et al. Conditional expression of a Gi-coupled receptor in osteoblasts results in trabecular osteopenia. Endocrinology 2008, 149:1329-1337.
13. Ding Q., Wang Q., Evers B.M. Alterations of MAPK activities associated with intestinal cell differentiation. Biochem Biophys Res Commun 2001, 284:282-288.
14. Choudhury G.G., Mahimainathan L., Das F., Venkatesan B., Ghosh-Choudhury N. c-Src couples PI 3 kinase/Akt and MAPK signaling to PDGF-induced DNA synthesis in mesangial cells. Cell Signal 2006, 18:1854-1864.
15. Tsien R.Y. A non-disruptive technique for loading calcium buffers and indicators into cells. Nature 1981, 290:527-528.
16. + transient outward current via the calcineurin pathway. J Biol Chem 2004, 279:40634-40639.
17. 2+-selective TRPV6 channel. J Biol Chem 2004, 279:36546-36552.
18. Furuta A., Tanaka M., Omata W., Nagasawa M., Kojima I., Shibata H. Microtubule disruption with BAPTA and dimethyl BAPTA by a calcium chelation-independent mechanism in 3T 3-L1 adipocytes. Endocr J 2009, 56:235-243.
19. Pereverzev A., Komarova S.V., Korcok J., Armstrong S., Tremblay G.B., Dixon S.J., et al. Extracellular acidification enhances osteoclast survival through an NFAT-independent, protein kinase C-dependent pathway. Bone 2008, 42:150-161.
20. Ang E.S., Zhang P., Steer J.H., Tan J.W., Yip K., Zheng M.H., et al. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL). J Cell Physiol 2007, 212:787-795.
21. Mentaverri R., Yano S., Chattopadhyay N., Petit L., Kifor O., Kamel S., et al. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J 2006, 20:2562-2564.
22. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571.
23. Khaitlina S., Hinssen H. Ca-dependent binding of actin to gelsolin. FEBS Lett 2002, 521:14-18.
24. Zaidi M., Adebanjo O.A., Moonga B.S., Sun L., Huang C.L. Emerging insights into the role of calcium ions in osteoclast regulation. J Bone Miner Res 1999, 14:669-674.
25. Wilson S.R., Peters C., Saftig P., Bromme D. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 2009, 284:2584-2592.
26. Menaa C., Esser E., Sprague S.M. Beta2-microglobulin stimulates osteoclast formation. Kidney Int 2008, 73:1275-1281.
27. Sharma S.M., Bronisz A., Hu R., Patel K., Mansky K.C., Sif S., et al. MITF and PU. 1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem 2007, 282:15921-15929.
28. Bost F., Aouadi M., Caron L., Binetruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie 2005, 87:51-56.
29. Nishida S., Tsubaki M., Hoshino M., Namimatsu A., Uji H., Yoshioka S., et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST 2. Biochem Biophys Res Commun 2005, 328:91-97.